α-Tocopheryl Succinate Inhibits Osteolytic Bone Metastasis of Breast Cancer by Suppressing Migration of Cancer Cells and Receptor Activator of Nuclear Factor-κΒ Ligand Expression of Osteoblasts
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Breast cancer is one of the most common cancers affecting women and has a high incidence of bone metastasis, causing osteolytic lesions. The elevated expression of receptor activator of nuclear factor-κB ligand (RANKL) in cancer activates osteoclasts, leading to bone destruction. We previously reported that α-tocopheryl succinate (αTP-suc) inhibited interleukin-1-induced RANKL expression in osteoblasts. Here, we examined the effect of αTP-suc on osteolytic bone metastasis in breast cancer. Methods: To examine the effect of αTP-suc on the metastatic capacity of breast cancer, MDA-MB- 231-FL cells were injected into the left cardiac ventricle of BALB/c nude mice along with intraperitoneal injection of αTP-suc. The mice were then analyzed by bioluminescence imaging. To investigate the effect of αTP-suc on osteolysis, 4T1 cells were directly injected into the femur of BALB/c mice along with intraperitoneal injection of αTP-suc. Microcomputed tomography analysis and histomorphometric analysis of the femora were performed. Results: αTP-suc inhibited cell migration and cell growth of 4T1 cells. In line with these results, bone metastasis of MDA-MB-231-FL cells was reduced in mice injected with αTP-suc. In addition, αTP-suc decreased osteoclastogenesis by inhibiting 4T1-induced RANKL expression in osteoblasts. Consistent with these results, 4T1-induced bone destruction was ameliorated by αTP-suc, with in vivo analysis showing reduced tumor burden and osteoclast numbers. Conclusions: Our findings suggest that αTP-suc may be efficiently utilized to prevent and treat osteolytic bone metastasis of breast cancer with dual effects.
Abstract
Background: Breast cancer is one of the most common cancers affecting women and has a high incidence of bone metastasis, causing osteolytic lesions. The elevated expression of receptor activator of nuclear factor-κB ligand (RANKL) in cancer activates osteoclasts, leading to bone destruction. We previously reported that α-tocopheryl succinate (αTP-suc) inhibited interleukin-1-induced RANKL expression in osteoblasts. Here, we examined the effect of αTP-suc on osteolytic bone metastasis in breast cancer. Methods: To examine the effect of αTP-suc on the metastatic capacity of breast cancer, MDA-MB- 231-FL cells were injected into the left cardiac ventricle of BALB/c nude mice along with intraperitoneal injection of αTP-suc. The mice were then analyzed by bioluminescence imaging. To investigate the effect of αTP-suc on osteolysis, 4T1 cells were directly injected into the femur of BALB/c mice along with intraperitoneal injection of αTP-suc. Microcomputed tomography analysis and histomorphometric analysis of the femora were performed. Results: αTP-suc inhibited cell migration and cell growth of 4T1 cells. In line with these results, bone metastasis of MDA-MB-231-FL cells was reduced in mice injected with αTP-suc. In addition, αTP-suc decreased osteoclastogenesis by inhibiting 4T1-induced RANKL expression in osteoblasts. Consistent with these results, 4T1-induced bone destruction was ameliorated by αTP-suc, with in vivo analysis showing reduced tumor burden and osteoclast numbers. Conclusions: Our findings suggest that αTP-suc may be efficiently utilized to prevent and treat osteolytic bone metastasis of breast cancer with dual effects.
참고문헌 (35)
- Roodman GD, "Mechanisms of bone metastasis", N Engl J Med, 350, pp.1655~1664 (2004)[DOI]
- Coleman RE, "Metastatic bone disease: clinical features, pathophysiology and treatment strategies", Cancer Treat Rev, 27, pp.165~176 (2001)[DOI]
- Mundy GR, "Metastasis to bone: causes, consequences and therapeutic opportunities", Nat Rev Cancer, 2, pp.584~593 (2002)[DOI]
- Chen YC, "Breast cancer metastasis to the bone: mechanisms of bone loss", Breast Cancer Res, 12, pp.215~ (2010)[DOI]
- Wang N, "Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models", J Bone Miner Res, 29, pp.2688~2696 (2014)[DOI]
- Croucher PI, "Bone metastasis: the importance of the neighbourhood", Nat Rev Cancer, 16, pp.373~386 (2016)[DOI]
- Ju J, "Cancer-preventive activities of tocopherols and tocotrienols", Carcinogenesis, 31, pp.533~542 (2010)[DOI]
- Husain K, "Vitamin E delta-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-kappaB activation in pancreatic cancer", Mol Cancer Ther, 10, pp.2363~2372 (2011)[DOI]
- Gysin R, "Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins", FASEB J, 16, pp.1952~1954 (2002)[DOI]
- Alqahtani S, "Vitamin E transporters in cancer therapy", Aaps j, 17, pp.313~322 (2015)[DOI]
- 김하늬, "α-Tocopheryl Succinate Inhibits Osteoclast Formation by Suppressing Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) Expression and Bone Resorption", 대한골대사학회지, 19(2), pp.111~120 (2012), 대한골대사학회
- Savitskaya MA, "alpha-Tocopheryl succinate affects malignant cell viability, proliferation, and differentiation", Biochemistry (Mosc), 81, pp.806~818 (2016)[DOI]
- Lee JH, "Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling", J Biol Chem, 284, pp.13725~13734 (2009)[DOI]
- Lee JH, "CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis", Cancer Res, 72, pp.3175~3186 (2012)[DOI]
- 진원종, "NF-κB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells", Experimental and Molecular Medicine, 49, pp.1~12 (2017), 생화학분자생물학회
- Wang D, "alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion", J Med Chem, 52, pp.5642~5648 (2009)[DOI]
- Davis-Yadley AH, "Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications", Adv Nutr, 6, pp.774~802 (2015)[DOI]
- Doldo E, "Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins", Biomed Res Int, 2015, pp.624627~ (2015)
- Fritz H, "Intravenous vitamin C and cancer: A systematic review", Integr Cancer Ther, 13, pp.280~300 (2014)[DOI]
- Garland CF, "The role of vitamin D in cancer prevention", Am J Public Health, 96, pp.252~261 (2006)[DOI]
- Lamson DW, "The anticancer effects of vitamin K", Altern Med Rev, 8, pp.303~318 (2003)
- Frank J, "Beyond vitamin E supplementation: an alternative strategy to improve vitamin E status", J Plant Physiol, 162, pp.834~843 (2005)[DOI]
- Azzi A, "Non-antioxidant molecular functions of alpha-tocopherol (vitamin E)", FEBS Lett, 519, pp.8~10 (2002)[DOI]
- Diplock AT, "Safety of antioxidant vitamins and beta-carotene", Am J Clin Nutr, 62, pp.1510s~1516s (1995)[DOI]
- Muller L, "In vitro antioxidant activity of tocopherols and tocotrienols and comparison of vitamin E concentration and lipophilic antioxidant capacity in human plasma", Mol Nutr Food Res, 54, pp.731~742 (2010)[DOI]
- Prasad KN, "Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review", J Am Coll Nutr, 22, pp.108~117 (2003)[DOI]
- Futakuchi M, "Heterogeneity of tumor cells in the bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer", Adv Drug Deliv Rev, 99, pp.206~211 (2016)[DOI]
- Clezardin P, "Bone metastasis: pathogenesis and therapeutic implications", Clin Exp Metastasis, 24, pp.599~608 (2007)[DOI]
- Hauschka PV, "Polypeptide growth factors in bone matrix", Ciba Found Symp, 136, pp.207~225 (1988)
- Monteiro AC, "T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer", PLoS One, 8, pp.e68171~ (2013)[DOI]
- Tan W, "Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling", Nature, 470, pp.548~553 (2011)[DOI]
- Chechlinska M, "Systemic inflammation as a confounding factor in cancer biomarker discovery and validation", Nat Rev Cancer, 10, pp.2~3 (2010)[DOI]
- Ryo Okazaki, "Osteoporosis Associated with Chronic Obstructive Pulmonary Disease", 대한골대사학회지, 23(3), pp.111~120 (2016), 대한골대사학회[DOI]
- Ha H, "alpha-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity", Biochem Biophys Res Commun, 406, pp.546~551 (2011)[DOI]
- Simmons JK, "Animal models of bone metastasis", Vet Pathol, 52, pp.827~841 (2015)[DOI]